Glatiramer acetate
Top View
- Multiple Sclerosis Agents
- Comparative Efficacy of First-Line Natalizumab Vs IFN-Β Or Glatiramer Acetate in Relapsing MS Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Et Al
- Tumefactive Demyelinating Lesions in Patients with Relapsing Remitting
- Clinical Policy: Ozanimod (Zeposia)
- ZEPOSIA® (Ozanimod) Capsules, for Oral Use Liver Function Tests Before Initiating ZEPOSIA (5.3) Initial U.S
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
- Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 08/16 Last Review Date: 08/17 Revision Log
- The Effectiveness of Interferon Beta Versus Glatiramer Acetate and Natalizumab Versus Fingolimod in a Polish Real-World Population
- "Alemtuzumab" in the Treatment of Multiple Sclerosis
- IMPORTANT SAFETY INFORMATION Do Not Take GLATIRAMER ACETATE INJECTION If You Are Allergic to Glatiramer Acetate Or Mannitol
- P R I M E R Advances in Multiple Sclerosis
- Glatiramer Acetate Autoimmune Encephalomyelitis by Oral Th2 Bias
- How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multiple Sclerosis
- Multiple Sclerosis: Gilenya (Fingolimod) Step Edit Policy
- Transtentorial Herniation from Tumefactive Multiple Sclerosis Mimicking Primary Brain Tumor Kunal Vakharia, Haris Kamal1, Gursant S
- Immunomodulation of Glatiramer Acetate in Multiple Sclerosis Chunhua Chen* Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA
- Disease-Modifying Therapies
- Beta Interferons and Glatiramer Acetate for Treating Multiple Sclerosis